NeuroPointDX Partners with Ovid Therapeutics to Identify Biomarkers for Angelman Syndrome
 /  News / NeuroPointDX Partners with Ovid Therapeutics to Identify Biomarkers for Angelman Syndrome

NeuroPointDX Partners with Ovid Therapeutics to Identify Biomarkers for Angelman Syndrome

Together, Ovid and NeuroPointDX will use metabolomics data to better understand the rare neuro-genetic disorder known as Angelman Syndrome. NeuroPointDX’s metabolomics technology will be used in Ovid’s phase 2 STARS trial of its drug candidate, OV101.

Read more

Related Posts

(608) 204-0104

504 S. Rosa Rd. Suite 150
Madison, WI 53719

contact@NeuroPointDx.com